-
Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies
•
China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license agreement with Germany’s BioNTech SE (NASDAQ: BNTX). The deal grants BioNTech exclusive worldwide options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy. Additionally, Biotheus will provide BioNTech with exclusive licenses…
-
Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs
•
Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing agreement with Germany’s BioNTech SE (NASDAQ: BNTX). Under the terms of this deal, Doer Bio will provide BioNTech with a global license to research, develop, manufacture, and commercialize innovative biological drugs targeting an undisclosed therapeutic…
